BACKGROUND AND OBJECTIVES: An analysis of the clinicopathologic features and treatment of patients with postirradiation sarcoma of bone and soft tissue was performed to guide modern evaluation and management. METHODS: A retrospective analysis of 135 sarcomas in 130 patients was performed. RESULTS: The mean age of the 130 patients was 48 years, and there was a female predominance because of irradiation for carcinomas of the breast and uterus. Indication for irradiation was a soft tissue lesion (such as lymphoma or breast cancer) in 58.5% of patients and a bone lesion (such as giant cell tumor or fibrous dysplasia) in 41.5%. The latent period (interval between irradiation and discovery of the sarcoma) ranged from 4-55 years (mean, 17 years). Of the lesions, 74% were stage IIB (high-grade extra-compartmental) and 24% were stage III (metastases). Ninety-four patients received their treatment at our institution. Of the 61 patients with resectable disease, 49 had amputations and 12 had limb salvage procedures. The 5-year cumulative survival rate was 68.2% for patients with peripheral (extremities, including proximal femur and hip) resectable lesions and 27.3% for patients with central (pelvis, head/neck, and ribs) resectable lesions. The local recurrence rate correlated with the surgical margin achieved: intralesional, 73%, marginal, 64%, and wide, 23%. CONCLUSIONS: The prognosis for patients with peripheral resectable postirradiation sarcomas is good if a wide surgical margin can be achieved. This group of patients should be treated aggressively because they have a new cancer. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: An analysis of the clinicopathologic features and treatment of patients with postirradiation sarcoma of bone and soft tissue was performed to guide modern evaluation and management. METHODS: A retrospective analysis of 135 sarcomas in 130 patients was performed. RESULTS: The mean age of the 130 patients was 48 years, and there was a female predominance because of irradiation for carcinomas of the breast and uterus. Indication for irradiation was a soft tissue lesion (such as lymphoma or breast cancer) in 58.5% of patients and a bone lesion (such as giant cell tumor or fibrous dysplasia) in 41.5%. The latent period (interval between irradiation and discovery of the sarcoma) ranged from 4-55 years (mean, 17 years). Of the lesions, 74% were stage IIB (high-grade extra-compartmental) and 24% were stage III (metastases). Ninety-four patients received their treatment at our institution. Of the 61 patients with resectable disease, 49 had amputations and 12 had limb salvage procedures. The 5-year cumulative survival rate was 68.2% for patients with peripheral (extremities, including proximal femur and hip) resectable lesions and 27.3% for patients with central (pelvis, head/neck, and ribs) resectable lesions. The local recurrence rate correlated with the surgical margin achieved: intralesional, 73%, marginal, 64%, and wide, 23%. CONCLUSIONS: The prognosis for patients with peripheral resectable postirradiation sarcomas is good if a wide surgical margin can be achieved. This group of patients should be treated aggressively because they have a new cancer. Copyright 2000 Wiley-Liss, Inc.
Authors: Rebecca A Gladdy; Li-Xuan Qin; Nicole Moraco; Mark A Edgar; Cristina R Antonescu; Kaled M Alektiar; Murray F Brennan; Samuel Singer Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Keila E Torres; Vinod Ravi; Katherine Kin; Min Yi; B Ashleigh Guadagnolo; Caitlin D May; Banu K Arun; Kelly K Hunt; Ryan Lam; Guy Lahat; Aviad Hoffman; Janice N Cormier; Barry W Feig; Alexander J Lazar; Dina Lev; Raphael E Pollock Journal: Ann Surg Oncol Date: 2012-12-06 Impact factor: 5.344
Authors: Bruno Fuchs; Nathan Hoekzema; Dirk R Larson; Carrie Y Inwards; Franklin H Sim Journal: Clin Orthop Relat Res Date: 2008-10-15 Impact factor: 4.176